RESOLVE-IT Failure Dashes Genfit's NASH Hopes

Elafibranor Missed Trial Endpoints At The Interim Stage

Target
RESOLVE-IT missed its primary endpoint for treating NASH • Source: Shutterstock

More from Clinical Trials

More from R&D